Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma - 20/06/22
Abstract |
Background |
We aimed to investigate whether improvements in the prognosis of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) who have undergone hepatectomy are associated with reductions in the liver inflammation and fibrosis by antiviral therapy (AVT).
Methods |
Patients who underwent hepatectomy and re-hepatectomy for HBV-related HCC between 2010 and 2019 were divided into two groups. Histological changes in liver were compared between initial and recurrence stages within each group. Propensity score matching (PSM) analysis was performed to compare prognostic outcomes.
Results |
After PSM, AVT group showed a significantly better prognosis than did non-AVT group (RFS: 19.1% vs. 5.8%, P = 0.001; OS: 64.0% vs. 43.2%, P < 0.001). The improvements in G and S were independent protective factors for RFS (G: P < 0.001; S: P < 0.001) and OS (G: P = 0.013; S: P < 0.001).
Conclusions |
The application of AVT after initial surgery improved liver inflammation and fibrosis, further benefiting long-term outcomes of patients with HBV-related HCC.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Antiviral therapy (AVT) is associated better postoperative outcomes in patients with HBV-related HCC. |
• | Long-term AVT could lead to the improvement of liver inflammation and fibrosis. |
• | The improvement in liver inflammation and fibrosis resulting from AVT is associated with a better postoperative prognosis. |
Keywords : Hepatocellular carcinoma, Hepatitis B virus, Antiviral therapy, Liver inflammation, Survival
Plan
Vol 224 - N° 1PB
P. 494-500 - juillet 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?